numberwang said:
You are repeating their own marketing spin, not a reliable source. I am referencing the actual clinical outcome data and it is terrible. A vaccine that doesn't reduce infections and viral load has no way to increase herd immunity. Taking Vitamin D would likely give better immunity. The clinical outcome of this vaccine: 71% fatigue 68% headaches 60% systemic muscle ache 61 malaise 51% feverish 18% fever over 38°C Injecting painkillers to hide these symptoms for a vaccine is unacceptable. We are not talking about a rare medication for a last ditch effort to save someone but a vaccine that is supposed to be given to healthy people. Fatigue was reported in the ChAdOx1 nCoV-19 group by 340 (70%) participants without paracetamol and 40 (71%) with paracetamol and in the MenACWY group by 227 (48%) participants without paracetamol and 26 (46%) with paracetamol, whereas headaches were reported in the ChAdOx1 nCoV-19 group by 331 (68%) participants without paracetamol and 34 (61%) with paracetamol and in the MenACWY group by 195 (41%) participants without paracetamol and 21 (37%) participants with paracetamol.
Other systemic adverse reactions were common in the ChAdOx1 nCoV-19 group: muscle ache (294 [60%] participants without paracetamol and 27 [48%] with paracetamol), malaise (296 [61%] and 27 [48%]), chills (272 [56%] and 15 [27%]); and feeling feverish (250 [51%] and 20 [36%]). In the of ChAdOx1 nCoV-19 group, 87 (18%) participants without paracetamol and nine (16%) participants with paracetamol reported a temperature of at least 38°C, and eight (2%) patients without paracetamol had a temperature of at least 39°C. In comparison, two (<1%) of those receiving MenACWY reported a fever of at least 38°C, none of whom were receiving prophylactic paracetamol
|
You're cherrypicking, and none of those side effects are serious, it's all minor, effectively harmless stuff.
From the same clinical data:
"No serious adverse reactions to ChAdOx1 nCoV-19 occurred".
"In conclusion, ChAdOx1 nCoV-19 was safe, tolerated, and immunogenic, while reactogenicity was reduced with paracetamol. A single dose elicited both humoral and cellular responses against SARS-CoV-2, with a booster immunisation augmenting neutralising antibody titres. The preliminary results of this first-in-human clinical trial supported clinical development progression into ongoing phase 2 and 3 trials".
Last edited by curl-6 - on 16 September 2020